Skip to main content
. 2019 Mar 20;13:521–527. doi: 10.2147/OPTH.S198648

Figure 2.

Figure 2

Effect of IFX+CsA combination therapy on the severity of ocular inflammatory attacks. IFX+CsA combination therapy significantly decreased the severity of ocular inflammatory attack as evaluated by the mean BOS24 value in each ocular attack (P=0.002, linear mixed models analysis). Data are presented as the mean±standard deviation.

Abbreviations: IFX, infliximab; CsA, cyclosporine; BOS24, Behçet’s disease ocular attack score 24; M, months.